Masatomo Miura - Search Results

Year	Number of Results
2002	2
2003	1
2004	1
2005	3
2006	7
2007	10
2008	10
2009	8
2010	16
2011	14
2012	16
2013	8
2014	10
2015	11
2016	9
2017	15
2018	16
2019	12
2020	13
2021	15
2022	9
2023	9
2024	3

1

Association between albumin-bilirubin grade and plasma trough concentrations of regorafenib and its metabolites M-2 and M-5 at steady-state in Japanese patients.

Fujita K, Taguchi D, Fukuda K, Yoshida T, Shimazu K, Shinozaki H, Shibata H, Miura M. Fujita K, et al. Among authors: miura m. Invest New Drugs. 2024 Mar 22. doi: 10.1007/s10637-024-01429-z. Online ahead of print. Invest New Drugs. 2024. PMID: 38517650

2

Circulating IL-6 and not its circulating signaling components sIL-6R and sgp130 demonstrate clinical significance in NSCLC patients treated with immune checkpoint inhibitors.

Nakahara Y, Kouro T, Motoyama S, Miura M, Fujita K, Igarashi Y, Higashijima N, Matsuo N, Himuro H, Wei F, Horaguchi S, Tsuji K, Mano Y, Komahashi M, Saito H, Azuma K, Sasada T. Nakahara Y, et al. Among authors: miura m. Front Cell Dev Biol. 2024 Jan 16;11:1324898. doi: 10.3389/fcell.2023.1324898. eCollection 2023. Front Cell Dev Biol. 2024. PMID: 38469154 Free PMC article.

3

Influence of genetic polymorphisms in vascular endothelial-related genes on the clinical outcome of axitinib in patients with metastatic renal cell carcinoma.

Numakura K, Igarashi R, Takahashi M, Nara T, Kanda S, Saito M, Narita S, Inoue T, Niioka T, Miura M, Habuchi T. Numakura K, et al. Among authors: miura m. Cancer Biol Ther. 2024 Dec 31;25(1):2312602. doi: 10.1080/15384047.2024.2312602. Epub 2024 Feb 7. Cancer Biol Ther. 2024. PMID: 38327067 Free PMC article.

4

[Determination of Plasma Concentrations of Imatinib by a Novel Automated Analyzer Based on High-Performance Liquid Chromatography].

Fukushi Y, Akamine Y, Matsushita M, Morikawa S, Miura M. Fukushi Y, et al. Among authors: miura m. Yakugaku Zasshi. 2023;143(11):963-969. doi: 10.1248/yakushi.23-00131. Yakugaku Zasshi. 2023. PMID: 37914342 Free article. Japanese.

5

A Prospective Cohort Study Assessing the Relationship between Plasma Levels of Osimertinib and Treatment Efficacy and Safety.

Fukuhara T, Imai K, Nakagawa T, Igusa R, Yokota H, Watanabe K, Suzuki A, Morita M, Onodera R, Inoue A, Miura M, Minamiya Y, Maemondo M. Fukuhara T, et al. Among authors: miura m. Biomedicines. 2023 Sep 10;11(9):2501. doi: 10.3390/biomedicines11092501. Biomedicines. 2023. PMID: 37760942 Free PMC article.

6

Effects of polymorphisms in pregnane X receptor and ABC transporters on afatinib in Japanese patients with non-small cell lung cancer: pharmacogenomic-pharmacokinetic and exposure-response analysis.

Yokota H, Sato K, Sakamoto S, Okuda Y, Asano M, Takeda M, Nakayama K, Miura M. Yokota H, et al. Among authors: miura m. Cancer Chemother Pharmacol. 2023 Oct;92(4):315-324. doi: 10.1007/s00280-023-04569-w. Epub 2023 Jul 27. Cancer Chemother Pharmacol. 2023. PMID: 37500985

7

[Evaluation of Plasma Concentrations of Mycophenolic Acid in Renal Transplant Patients Using LM1010 High-performance Liquid Chromatography].

Akamine Y, Matsushita M, Morikawa S, Miura M. Akamine Y, et al. Among authors: miura m. Yakugaku Zasshi. 2023;143(4):377-383. doi: 10.1248/yakushi.22-00182. Yakugaku Zasshi. 2023. PMID: 37005240 Free article. Japanese.

8

Effects of ABCB1 polymorphisms on the transport of ponatinib into the cerebrospinal fluid in Japanese Philadelphia chromosome-positive acute lymphoblastic leukaemia patients.

Fukushi Y, Akamine Y, Abumiya M, Tozawa N, Yamashita T, Nara M, Kameoka Y, Takahashi N, Miura M. Fukushi Y, et al. Among authors: miura m. Br J Clin Pharmacol. 2023 May;89(5):1695-1700. doi: 10.1111/bcp.15650. Epub 2023 Jan 6. Br J Clin Pharmacol. 2023. PMID: 36541130

9

A Multi-institutional Study to Diagnose the Risk of Lymph Node Metastasis Using a CRP Genetic Polymorphism Test Kit in pT1, cN0 Thoracic Esophageal Squamous Cell Carcinoma.

Motoyama S, Hosaka M, Kamei T, Ueno M, Watanabe M, Ohkura YU, Mine S, Tanabe S, Toyokawa T, Wakita A, Nishikawa K, Ninomiya I, Fujita K, Kanda M, Hirai M, Hoshi M, Chiu SW, Takata M, Yamaguchi T, Miura M. Motoyama S, et al. Among authors: miura m. Anticancer Res. 2022 Dec;42(12):6105-6112. doi: 10.21873/anticanres.16123. Anticancer Res. 2022. PMID: 36456128

10

Impact of trough abiraterone level on adverse events in patients with prostate cancer treated with abiraterone acetate.

Takahashi Y, Narita S, Shiota M, Miura M, Kagaya H, Kashima S, Yamamoto R, Nara T, Huang M, Numakura K, Saito M, Eto M, Habuchi T. Takahashi Y, et al. Among authors: miura m. Eur J Clin Pharmacol. 2023 Jan;79(1):89-98. doi: 10.1007/s00228-022-03420-0. Epub 2022 Nov 15. Eur J Clin Pharmacol. 2023. PMID: 36378297

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

193 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

193 results

Results by year